CONCORD, Calif. & BUFFALO, N.Y.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that Unyts has signed a
three-year purchase agreement for the INTERCEPT Blood System for
platelets and plasma. Unyts provides blood components to eight counties
in Western New York, supplying approximately 5,000 platelet and 11,000
plasma units per year.
“Since adding community blood banking services in 2007, Unyts has
continuously strived to find ways to utilize the latest innovative
technologies to improve safety and availability,” said Mark Simon, Unyts
President and CEO. “The INTERCEPT blood system will provide a proactive
approach to addressing the safety of our platelet and plasma recipients
by protecting these patients from transfusion transmitted bacteria and
emerging pathogens.”
“We are pleased to add Unyts to our growing list of customers in the
US,” commented William "Obi" Greenman, Cerus’ president and chief
executive officer. “Unyts can now offer its hospitals state of the art
platelet and plasma components processed with the INTERCEPT system.”
ABOUT UNYTS
Headquartered in downtown Buffalo and established in 1981, Unyts is
among the leading procurement organizations in the United States, and is
one of only a few centers nationwide that offers organ, tissue and
eye procurement, in addition to a community blood service. Unyts
operates as a non-profit serving the eight counties of Western New York
and works to assist donor families, coordinate the donation process and
increase knowledge and awareness within the community regarding
transplantation. www.unyts.org
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood safety. The INTERCEPT Blood System is designed to reduce the
risk of transfusion-transmitted infections by inactivating a broad range
of pathogens such as viruses, bacteria and parasites that may be present
in donated blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established transfusion
threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria,
as well as emerging pathogens such as chikungunya, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in the United States, Europe, the Commonwealth of
Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150721005261/en/
Source: Cerus Corporation